Mr. Rashid Ahmed reports

BIOMARK DIAGNOSTICS ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET

Biomark Diagnostics Inc.'s common shares were officially approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market under the symbol BMKDF on May 8, 2025. Additionally, the company's common shares will maintain its eligibility for settlement through the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corp., which facilitates the electronic clearing and settlement of publicly traded companies in the United States.

Trading on the OTCQB is expected to complement the company's existing listing on the Canadian Securities Exchange under its existing symbol BUX, and no action is needed by current shareholders.

Rashid Bux, president and chief executive officer, said: "This is a significant milestone for the company as we aim to increase our presence among American retail and institutional investors, thereby providing enhanced liquidity. As we move toward the commercial launch of our liquid biopsy test for lung cancer, trading on the OTCQB will make it easier for U.S. investors to discover and trade our stock, while benefiting from transparent pricing and reporting standards. The timing is opportune for Biomark, and we believe the uplisting will boost visibility to a broader universe of investors and provide improved liquidity for our stock as the company seeks to expand its future operations in the U.S., starting with potential collaborations at some important comprehensive cancer screening centers."

About Biomark Diagnostics Inc.

Biomark is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.